Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Free Cash Flow data on file, last reported at -$89.3 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$89.3 million, down 12.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$244.0 million (down 1.68% YoY), and the FY2025 annual result was -$234.3 million, down 13.02% from the prior year.
• Free Cash Flow declined to -$89.3 million in Q1 2026 per KYMR's latest filing, from -$66.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$3.6 million in Q4 2023 and troughed at -$89.3 million in Q1 2026.
• A 5-year average of -$48.5 million and a median of -$47.0 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow surged 91.03% in 2023, then sank 1651.96% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$39.9 million in 2022, then surged by 91.03% to -$3.6 million in 2023, then slumped by 1651.96% to -$62.7 million in 2024, then retreated by 6.59% to -$66.9 million in 2025, then tumbled by 33.54% to -$89.3 million in 2026.
• Business Quant data shows KYMR's Free Cash Flow at -$89.3 million in Q1 2026, -$66.9 million in Q4 2025, and -$27.3 million in Q3 2025.